The DAPA-HF trial in HFrEF demonstrated that dapagliflozin is effective on HHF and cardiovascular death prevention also in subjects without T2D and regardless of either the etiology (ischemic vs. non-ischemic) or the severity of HF (in terms of EF, NT-proBNP levels, and background therapy). Here, NPPB is linked to type 2 diabetes mellitus.